EMA Authorised: Ilumetri (tildrakizumab) — Almirall, S.A.

View source ↗

Summary

The European Medicines Agency has authorised Ilumetri (tildrakizumab) by Almirall for the treatment of psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Ilumetri (tildrakizumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: Almirall, S.A.. Decision date: 05/06/2025